Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Indication and radicality of surgical treatment in spinal myeloma].
Rehák S, Maisnar V, Málek V, Náhlovský J, Ryska P, Kaltofen K, Cesák T, Kanta M, Adamkov J, Hosszú T, Cermáková E. Rehák S, et al. Among authors: maisnar v. Acta Medica (Hradec Kralove) Suppl. 2005;48(1):37-43. Acta Medica (Hradec Kralove) Suppl. 2005. PMID: 16669490 Czech.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV. Pour L, et al. Among authors: maisnar v. Haematologica. 2024 Mar 1;109(3):895-905. doi: 10.3324/haematol.2023.283509. Haematologica. 2024. PMID: 37646660 Free PMC article. Clinical Trial.
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, Johnson S, Milani P, Cordon L, Perez JJ, Lasa M, Termini R, Oriol A, Hernandez MT, Palomera L, Martinez-Martinez R, de la Rubia J, de Arriba F, Rios R, Gonzalez ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Perez-Montaña A, González-Calle V, Rodriguez-Otero P, Maisnar V, Hajek R, Van Rhee F, Jimenez-Zepeda V, Palladini G, Merlini G, Orfao A, de la Cruz J, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B; PETHEMA/GEM Cooperative Group. Burgos L, et al. Among authors: maisnar v. J Clin Oncol. 2023 Jun 1;41(16):3019-3031. doi: 10.1200/JCO.22.01916. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930848
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM, Efebera YA, Hájek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Obermüller J, Bakker NA, Pour L. Ocio EM, et al. Among authors: maisnar v. Haematologica. 2024 Mar 1;109(3):867-876. doi: 10.3324/haematol.2023.283490. Haematologica. 2024. PMID: 37646657 Free PMC article. Clinical Trial.
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Minarik J, Radocha J, Jungova A, Straub J, Jelinek T, Pika T, Pour L, Pavlicek P, Harvanova L, Pospisilova L, Krhovska P, Novakova D, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Maisnar V, Hajek R. Minarik J, et al. Among authors: maisnar v. Cancers (Basel). 2022 Oct 21;14(20):5165. doi: 10.3390/cancers14205165. Cancers (Basel). 2022. PMID: 36291949 Free PMC article.
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
Maisnar V, Pour L, Spicka I, Jelinek T, Minarik J, Jungova A, Stork M, Straub J, Radocha J, Pika T, Pospisilova L, Nair S, Kunovszki P, Hajek R. Maisnar V, et al. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):145-153. doi: 10.1016/j.clml.2022.11.001. Epub 2022 Nov 6. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36567210
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
Stork M, Sevcikova S, Jelinek T, Minarik J, Radocha J, Pika T, Pospisilova L, Spicka I, Straub J, Pavlicek P, Jungova A, Knechtova Z, Sandecka V, Maisnar V, Hajek R, Pour L. Stork M, et al. Among authors: maisnar v. Biomedicines. 2022 Oct 11;10(10):2535. doi: 10.3390/biomedicines10102535. Biomedicines. 2022. PMID: 36289797 Free PMC article.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Stork M, Spicka I, Radocha J, Minarik J, Jelinek T, Jungova A, Pavlicek P, Pospisilova L, Sedlak F, Straub J, Pika T, Knechtova Z, Fidrichova A, Boichuk I, Sevcikova S, Maisnar V, Hajek R, Pour L. Stork M, et al. Among authors: maisnar v. Ann Hematol. 2023 Jun;102(6):1501-1511. doi: 10.1007/s00277-023-05188-4. Epub 2023 Apr 24. Ann Hematol. 2023. PMID: 37088816 Free PMC article.
100 results